Welcome to our dedicated page for Cybin SEC filings (Ticker: CYBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cybin Inc. filings document the U.S. disclosure record for its Helus Pharma clinical-stage pharmaceutical business. Form 6-K reports furnished by the Canadian issuer attach company news releases and, when specified, incorporate exhibits by reference into Form F-10 shelf registration materials.
The filings cover the company’s novel serotonergic agonist pipeline, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder, as well as clinical-research collaborations, regulatory-policy statements, scientific advisory board changes, management appointments, chief executive transition disclosures, listing and operating-name updates, and capital-structure matters related to shelf and equity distribution activity.
CYBIN Inc. discloses a shelf prospectus supplement highlighting clinical-stage psychedelic drug development and material risks. The filing emphasizes that psilocin is not approved by Health Canada or the U.S. FDA and that the company does not handle controlled substances except within licensed laboratory or clinical trial settings. The company warns of substantial quarter-to-quarter losses and uncertainty about its ability to raise additional funding. Key development milestones include topline efficacy readout from the first Phase 3 study (APPROACH) for deuterated psilocin (CYB003), progression of two additional Phase 3 studies (EMBRACE, EXTEND), a Phase 2 GAD topline readout for deuterated DMT (CYB004), and advancing a drug development candidate from the phenethylamine/tryptamine program (CYB005). The filing notes reliance on third parties for trials and manufacturing and risk from changing laws across multiple jurisdictions.
CYBIN Inc. discloses a shelf prospectus supplement highlighting clinical-stage psychedelic drug development and material risks. The filing emphasizes that psilocin is not approved by Health Canada or the U.S. FDA and that the company does not handle controlled substances except within licensed laboratory or clinical trial settings. The company warns of substantial quarter-to-quarter losses and uncertainty about its ability to raise additional funding. Key development milestones include topline efficacy readout from the first Phase 3 study (APPROACH) for deuterated psilocin (CYB003), progression of two additional Phase 3 studies (EMBRACE, EXTEND), a Phase 2 GAD topline readout for deuterated DMT (CYB004), and advancing a drug development candidate from the phenethylamine/tryptamine program (CYB005). The filing notes reliance on third parties for trials and manufacturing and risk from changing laws across multiple jurisdictions.
CYBIN Inc. discloses financing and operational risks and outlines clinical development milestones across three programs. The company warns of uncertainty in raising additional funds, potential continued substantial losses, pandemic-related risks, regulatory constraints around psychedelic substances, and reliance on key personnel. It states it does not currently handle controlled substances outside approved laboratory or clinical settings and would need licenses and approvals to do so directly.
The filing lists near-term development objectives: topline efficacy readout from the first Phase 3 study (APPROACH) and progression of two additional Phase 3 studies (EMBRACE, EXTEND) for deuterated psilocin (CYB003); completion and topline data from a Phase 2 GAD study for deuterated DMT (CYB004); delivery of a drug development candidate for the phenethylamine and tryptamine derivatives program (CYB005); and use of proceeds for working capital and general corporate purposes.
CYBIN Inc. discloses financing and operational risks and outlines clinical development milestones across three programs. The company warns of uncertainty in raising additional funds, potential continued substantial losses, pandemic-related risks, regulatory constraints around psychedelic substances, and reliance on key personnel. It states it does not currently handle controlled substances outside approved laboratory or clinical settings and would need licenses and approvals to do so directly.
The filing lists near-term development objectives: topline efficacy readout from the first Phase 3 study (APPROACH) and progression of two additional Phase 3 studies (EMBRACE, EXTEND) for deuterated psilocin (CYB003); completion and topline data from a Phase 2 GAD study for deuterated DMT (CYB004); delivery of a drug development candidate for the phenethylamine and tryptamine derivatives program (CYB005); and use of proceeds for working capital and general corporate purposes.
CYBIN Inc. is offering securities via a secondary prospectus supplement and outlines risks, regulatory constraints and clinical-development milestones. The document emphasizes that the company currently does not handle controlled or restricted substances under Canadian or U.S. law and only works with psychedelic compounds within approved laboratory and clinical-trial frameworks or via third parties where required. Key near-term development objectives include topline efficacy readout from the first Phase 3 study (APPROACH) and progression of two additional Phase 3 studies (EMBRACE, EXTEND) for the deuterated psilocin program (CYB003), completion and topline data from a Phase 2 GAD study for deuterated DMT (CYB004), and delivery of a drug development candidate for the phenethylamine/tryptamine derivatives program (CYB005). The prospectus warns of continuing substantial losses, pandemic risks, potential clinical-trial delays, reliance on key personnel, and regulatory changes across multiple jurisdictions.
CYBIN Inc. is offering securities via a secondary prospectus supplement and outlines risks, regulatory constraints and clinical-development milestones. The document emphasizes that the company currently does not handle controlled or restricted substances under Canadian or U.S. law and only works with psychedelic compounds within approved laboratory and clinical-trial frameworks or via third parties where required. Key near-term development objectives include topline efficacy readout from the first Phase 3 study (APPROACH) and progression of two additional Phase 3 studies (EMBRACE, EXTEND) for the deuterated psilocin program (CYB003), completion and topline data from a Phase 2 GAD study for deuterated DMT (CYB004), and delivery of a drug development candidate for the phenethylamine/tryptamine derivatives program (CYB005). The prospectus warns of continuing substantial losses, pandemic risks, potential clinical-trial delays, reliance on key personnel, and regulatory changes across multiple jurisdictions.
CYBIN Inc. discloses risks around a proposed secondary offering, including uncertainty in raising additional funding and continued substantial losses. The company emphasizes regulatory constraints on psychedelic substances in key jurisdictions and states it currently does not handle controlled substances outside approved laboratory or clinical trial settings. Clinical development milestones are outlined: Phase 3 topline readout for deuterated psilocin (CYB003) and progression of two additional Phase 3 studies, a Phase 2 completion and topline readout for deuterated DMT (CYB004), and delivery of a drug development candidate from the CYB005 program. Proceeds are intended for working capital and general corporate purposes.
CYBIN Inc. discloses risks around a proposed secondary offering, including uncertainty in raising additional funding and continued substantial losses. The company emphasizes regulatory constraints on psychedelic substances in key jurisdictions and states it currently does not handle controlled substances outside approved laboratory or clinical trial settings. Clinical development milestones are outlined: Phase 3 topline readout for deuterated psilocin (CYB003) and progression of two additional Phase 3 studies, a Phase 2 completion and topline readout for deuterated DMT (CYB004), and delivery of a drug development candidate from the CYB005 program. Proceeds are intended for working capital and general corporate purposes.
Cybin Inc. filed a Form D for a Rule 506(b) exempt securities offering to permit exercise of stock options that could generate up to $288,280 USD (CAD conversion provided). The securities are stock options exercisable at CAD$10.00 per share that vest in eight quarterly tranches beginning September 30, 2025. The filing reports 0 amount sold to date, 288,280 USD remaining to be sold, and 10 total investors (also listed as 10 non-accredited investors). The offering is intended to last more than one year, minimum investment accepted is $0 USD, and no sales commissions or finders' fees are reported.